The world’s largest generic drugmaker earned 63 cents per diluted share excluding one-time items in the January-March period, down from 76 cents a share a year earlier. Revenue fell 9% to $3.98 billion.
Analysts had forecast Teva would earn 63 cents a share ex-items on revenue of $4.02 billion, according to I/B/E/S data from Refinitiv.
Teva reaffirmed its 2021 forecasts of adjusted EPS of $2.50-$2.70 and revenue of $16.4-$16.8 billion, compared with adjusted EPS of $2.57 and revenue of $16.7 billion in 2020.
